within Pharmacolibrary.Drugs.ATC.D;

model D11AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 8.333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D11AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Gamolenic acid (gamma-linolenic acid, GLA) is an omega-6 fatty acid used as a dietary supplement and was historically investigated for its potential benefits in treating atopic eczema, rheumatoid arthritis, and other inflammatory conditions. Though once present in some topical and oral formulations, it is not widely approved as a prescription medication today but is available as a nutraceutical.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies with compartmental modeling or robust PK parameter reporting are available for gamolenic acid. Most existing data are limited to serum concentration-time curves following oral administration in healthy adults or special patient populations, without full model-based PK parameterization.</p><h4>References</h4><ol><li><p>Tanaka, T, et al., &amp; Kiso, Y (2012). Oral supplementation with dihomo-γ-linolenic acid (DGLA)-enriched oil increases serum DGLA content in healthy adults. <i>Lipids</i> 47(6) 643–646. DOI:<a href=&quot;https://doi.org/10.1007/s11745-012-3664-3&quot;>10.1007/s11745-012-3664-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22411689/&quot;>https://pubmed.ncbi.nlm.nih.gov/22411689</a></p></li><li><p>Umeda-Sawada, R, et al., &amp; Seyama, Y (2006). Distribution and metabolism of dihomo-gamma-linolenic acid (DGLA, 20:3n-6) by oral supplementation in rats. <i>Bioscience, biotechnology, and biochemistry</i> 70(9) 2121–2130. DOI:<a href=&quot;https://doi.org/10.1271/bbb.60057&quot;>10.1271/bbb.60057</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16960355/&quot;>https://pubmed.ncbi.nlm.nih.gov/16960355</a></p></li><li><p>Li, H, et al., &amp; Chen, H (2016). Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance. <i>PloS one</i> 11(12) e0167930–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0167930&quot;>10.1371/journal.pone.0167930</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27973621/&quot;>https://pubmed.ncbi.nlm.nih.gov/27973621</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D11AX02;
